Treatment of basal cell carcinoma intralesionally with recombina

Drug – bio-affecting and body treating compositions – Lymphokine – Interferon

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

424 857, A61K 3766

Patent

active

050284223

ABSTRACT:
This invention relates to a method of treating basal cell carcinoma with purified human recombinant DNA interferon alpha-2, preferably purified human recombinant DNA interferon alpha-2b by administering intralesionally (by injection) to a patient in need of such treatment, a sufficient amount of the purified human recombinant DNA alpha interferon, preferably recombinant DNA interferon alpha-2b, to be effective as an antitumor agent.

REFERENCES:
patent: 4289690 (1981-09-01), Pestka et al.
patent: 4503035 (1985-03-01), Pestka et al.
patent: 4530901 (1985-07-01), Weissman
patent: 4959210 (1990-09-01), Smiles et al.
Ikeda, Japan Journal of Cancer Chemotherapy, 12(4), 936-942 (1985).
Ikic, D., Interferon and Cancer (Editor, Sikora K.), 169-181, Plenum Press (1983).
Barenbein et al., Vestn. Dermatology, Venerol No. (4): 31-33 (1985).
Ikic et al., The Lancet, May 9, 1981, pp. 1025-1027.
Langer et al., J. Invest. Dermatology 63, 1285-1365 (1984).
Staehelin et al., Methods in Enzynology 78 Part A. 505,511 (1981) Academic Press, N.J.
Rubenstein, Biochem. Biophys. Acta. 695, 5-16 (1982).
Nagata et al., Nature 284, 316-320 (1980).
Rook et al., Textbook of Dermatology, Fourth Edition, vol. 3 (Blackwell Scientific Publications), p. 2431-2437.
The Merck Index, Eleventh Edition (Merk & Co., Inc., Rahway, N.J.), p. 4895 (1989).
Genetic Tech. News, 6, No. 10, 1986, p. 5 (Greenway et al.).
J. Am. Acad. Dermat., 15 No. 3, Sept. 1986, pp. 437-443 (Greenway et al.)
Smiles et al. The Biology of the Interferon System, pp. 493-501.
Morita et al., Acta Dermatol-Kyoto 81(2), pp. 241-246, 1986.
Eron et al., The New England Journal of Medicine, vol. 315, No. 17, pp. 1059-1064 (1986).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Treatment of basal cell carcinoma intralesionally with recombina does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of basal cell carcinoma intralesionally with recombina, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of basal cell carcinoma intralesionally with recombina will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1245547

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.